Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

INTRODUCTION: Results from the open-label extension of the phase 3b CONQUER trial are presented to evaluate the effectiveness and safety of galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, for up to 6 months in patients with multiple prior migraine preventive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuter, Uwe, Lucas, Christian, Dolezil, David, Hand, Austin L., Port, Martha D., Nichols, Russell M., Stroud, Chad, Tockhorn-Heidenreich, Antje, Detke, Holland C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523004/
https://www.ncbi.nlm.nih.gov/pubmed/34542830
http://dx.doi.org/10.1007/s12325-021-01911-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523004/
https://www.ncbi.nlm.nih.gov/pubmed/34542830
http://dx.doi.org/10.1007/s12325-021-01911-7

Ejemplares similares